Human Trials

Midatech begins US clinical trial of MTX110 to treat DIPG

Midatech Pharma has commenced dosing in its first-in-human study with MTX110 for the treatment of diffuse intrinsic pontine glioma (DIPG), an aggressive form of childhood brain cancer.

AstraZeneca’s Imfinzi extends survival rate in lung cancer patients

AstraZeneca’s oncology immunotherapy Imfinzi (durvalumab) met the second primary endpoint of overall survival in the phase III trial for unresectable stage III non-small cell lung cancer (NSCLC).

Midatech begins dosing in first human trial of cancer drug Q-Octreotide

Midatech has commenced initial dosing in the first in-human study of its sustained release product Q-Octreotide (MTD201) for the treatment of carcinoid cancer and acromegaly.

Janssen’s Erleada shown to reduce PSA progression by 94% in nmCRPC patients

Janssen Pharmaceutical's androgen receptor inhibitor Erleada (apalutamide) succeeded in a phase 3 trial by significantly cutting down the risk of prostate specific antigen (PSA) progression in patients having non-metastatic castration-resistant prostate cancer (nmCRPC).

Pfizer’s Lyrica meets primary endpoint in phase 3 pediatric epilepsy trial

Pfizer has reported positive top-line results from a phase 3 study, which assessed the use of Lyrica (pregabalin) oral solution CV as adjunctive therapy for partial onset seizures in pediatric epilepsy patients one month to less than four years of age.

IDMC recommends to expand Tiziana’s phase 2a trial of Milciclib

Tiziana Life Sciences announces that the independent data monitor committee (IDMC) completed a second, interim analysis of tolerability data from the first eleven treated patients and recommended expansion of the initial cohort to continue enrolment of an additional 20 patients to complete the trial.

Merck to invest $125m in Moderna Therapeutics

Merck has agreed to invest $125m in Moderna Therapeutics under a new agreement that expands the firms’ 2016 partnership to develop messenger RNA (mRNA) cancer vaccines.

Karyopharm’s multiple myeloma drug Selinexor succeeds in phase 2b study

Karyopharm Therapeutics’ selinexor, an oral selective inhibitor of nuclear export (SINE) compound, has succeeded in a phase 2b study by showing a 25.4% overall response rate (ORR) in heavily pretreated patients with refractory multiple myeloma.

Allergan’s ubrogepant migraine drug succeeds in second phase 3 trial

Allergan’s migraine drug ubrogepant has succeeded in a phase 3 trial by meeting its co-primary endpoints for a 50mg dose.